Doxorubicin hydrochloride-oleic acid conjugate loaded nanostructured lipid carriers for tumor specific drug release

Zhao, Shuangni; Minh, Le Van; Li, Na; Garamus, Vasil M.; Handge, Ulrich A.; Liu, Jianwen; Zhang, Rongguang; Willumeit‐Römer, Regine; Zou, Aihua

doi:10.1016/j.colsurfb.2016.04.027

Cited by 42 publications

(13 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PBS, sodium chloride, and serum are common release media. Researchers have found both complexation 18 , 57 , 120 , 121 and release 30 , 38 , 48 , 70 – 72 , 105 , 112 , 121 to be pH-dependent. These assays are usually run at pH values at and below 7.3.…”

Section: Ion Paired Drug Release From a Delivery Vehiclementioning

confidence: 99%

Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers

2019

View full text Add to dashboard Cite

show abstract

Section: Ion Paired Drug Release From a Delivery Vehiclementioning

confidence: 99%

Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers

2019

View full text Add to dashboard Cite

show abstract

“…Small hydrophilic molecules are widely used for treating diseases such as infectious diseases (Macielag, 2012;Zhang et al, 2015;Chandel et al, 2018), cancer (Xu et al, 2014;Zhao et al, 2016), and local anesthesia (Howell and Chauhan, 2009;Jug et al, 2010). Although effective, the dosage, therapeutic effect, and patient accomplishment of such compounds are usually limited by the tendency to distribute into the biological aqueous environment of the human body, leading to side effects (Weiniger et al, 2010;Wang et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Strategies to Obtain Encapsulation and Controlled Release of Small Hydrophilic Molecules

Zhao

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The therapeutic effect of small hydrophilic molecules is limited by the rapid clearance from the systemic circulation or a local site of administration. The unsuitable pharmacokinetics and biodistribution can be improved by encapsulating them in drug delivery systems. However, the high-water solubility, very hydrophilic nature, and low molecular weight make it difficult to encapsulate small hydrophilic molecules in many drug delivery systems. In this mini-review, we highlight three strategies to efficiently encapsulate small hydrophilic molecules and achieve controlled release: physical encapsulation in micro/nanocapsules, physical adsorption via electronic interactions, and covalent conjugation. The principles, advantages, and disadvantages of each strategy are discussed. This review paper could be a guide for scientists, engineers, and medical doctors who want to improve the therapeutic efficacy of small hydrophilic drugs.

show abstract

“…However, there is still a pressing need for fewer toxic drugs formulation and presentation. In order to circumvent the adverse effects of DOX and improve its efficacy, different drug delivery systems have been developed [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. Among lipid-based systems, Doxil ® and Myocet ® are liposomal commercial formulations, which improved the safety profile of DOX in comparison with free DOX.…”

Section: Introductionmentioning

confidence: 99%

“…As liposomes, solid lipid nanoparticles (SLN) and NLC can improve bioavailability and control drug release [ 27 , 28 , 33 ], but they present advantages, as production without organic solvents and using simple and easily scale-up techniques, which turns the process simpler, safer and cheaper [ 34 , 35 ]. Different from SLN, NLCs are drug delivery systems composed of a mixture of solid and liquid lipids, thus forming a solid lipid matrix containing imperfections in which the APIs can be loaded [ 36 , 37 ].…”

Section: Introductionmentioning

confidence: 99%

Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice

et al. 2021

View full text Add to dashboard Cite

Doxorubicin (DOX), a chemotherapy drug successfully used in the therapy of various types of cancer, is currently associated with the mucositis development, an inflammation that can cause ulcerative lesions in the mucosa of the gastrointestinal tract, abdominal pain and secondary infections. To increase the safety of the chemotherapy, we loaded DOX into nanostructured lipid carriers (NLCs). The NLC–DOX was characterized by HPLC, DLS, NTA, Zeta potential, FTIR, DSC, TEM and cryogenic-TEM. The ability of NLC–DOX to control the DOX release was evaluated through in vitro release studies. Moreover, the effect of NLC–DOX on intestinal mucosa was compared to a free DOX solution in C57BL/6 mice. The NLC–DOX showed spherical shape, high drug encapsulation efficiency (84.8 ± 4.6%), high drug loading (55.2 ± 3.4 mg/g) and low average diameter (66.0–78.8 nm). The DSC and FTIR analyses showed high interaction between the NLC components, resulting in controlled drug release. Treatment with NLC–DOX attenuated DOX-induced mucositis in mice, improving shortening on villus height and crypt depth, decreased inflammatory parameters, preserved intestinal permeability and increased expression of tight junctions (ZO-1 and Ocludin). These results indicated that encapsulation of DOX in NLCs is viable and reduces the drug toxicity to mucosal structures.

show abstract

Doxorubicin hydrochloride-oleic acid conjugate loaded nanostructured lipid carriers for tumor specific drug release

Cited by 42 publications

References 62 publications

Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers

Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers

Strategies to Obtain Encapsulation and Controlled Release of Small Hydrophilic Molecules

Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice

Contact Info

Product

Resources

About